Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.

摘要: Background: Collecting duct carcinoma (CDC) is a rare and aggressive variant of renal cell (RCC), which has poor response to cytokine therapy chemotherapy. Introduction tyrosine kinase inhibitors (TKIs), in particular sorafenib sunitinib, changing the treatment paradigm for management RCC. However, patients with CDC have been excluded from majority randomised trials involving use TKIs. Case Report: Our patient metastatic was treated sorafenib, demonstrated an excellent response, both clinically radiologically. She continues on minimal toxicity, progressionfree survival exceeding 13 months. Conclusions: This first reported case responding treatment. Therefore, role needs prospective evaluation.